Ophthalmic Market
The Eye Drop Dilemma
The eye dropper has been the predominate delivery system for ophthalmic drugs for over a century. Ninety-five percent of all ophthalmic drugs are delivered by an eye drop bottle. While inexpensive to manufacture, the eye drop bottle creates a plethora of problems for people who use it. The root of these problems lies in several factors related to the physics of eye drop, fluid dynamics and gravity.
The eye drop bottle relies upon gravity to move the drop from the tip of the bottle to the eye. Generally an eye drop must reach a size of about 40 microliters before it will fall from the tip of the bottle. Unfortunately, the human eye can only hold a drop of 12 microliters before it will overflow. Hence, two-thirds of every drop is wasted. This drug overflow creates a cascade of higher order problems for people such as the inconvenience of the "wet face" syndrome, waste of expensive medications, allergic reactions on the eyelids and a variety of potential health risks associated with inaccurate dosing of a pharmaceutical drug.
Effective eye drop administration from a bottle is further complicated by the challenges of having to tip back the head, while positioning a very small bottle over the eye, while squeezing the bottle with the appropriate level of force (too little force and the drop will not form and drop, too much force and you feel like you've turned on the garden hose), while holding the bottle steady so as not to miss the eye. All this while attempting to not look at the bottle as you are dispensing the drug. Add the physical challenges often faced by the elderly, compounded by the need for multiple daily administration of ophthalmic drugs by chronic sufferers and you can begin to grasp the nature of the Eye Drop Bottle Dilemma.
Why no one has solved this problem in the past one hundred years with all the advancements in science and technology is an interesting mystery. Finally, Mystic Pharmaceuticals has the solution.
Mystic Value Proposition For Consumers
Mystic devices are designed to provide the consumer with an easy, convenient and safe way to self-administer ophthalmic drugs. Each device carries a multiple day supply of individual unit dose blisters. The device can administer drugs to the eye in a wide range of normal physical positions. The eyecup aids the user in exact positioning of the device and in holding the eyelid in the optimum position. The device operates with the push of a button and delivers a precise dose to a precise location in the eye safely, comfortably with minimum waste. Mystic drug delivery systems are designed to provide consumers with the following benefits.
• Precision dosing, precision drug delivery
• Reduced waste (and cost) arising from errors in drug administration
• Reduced health risks resulting from under/over drug administration
• Reduces flow of excess medication through nasolacrimal duct and resulting systemic uptake
• Elimination of the drug preservatives improving comfort and reducing the risk of eye irritation
• Reduction of waste arising from discards of partially used bottles
• Reduced risk of accidental "poke" or injury to the eye
• More flexible range of physical orientations during drug administration
• Enhanced compliance tracking to prescribed use
• Ease, speed and convenience of drug administration process
• Elimination of the "wet face" syndrome and allergic reactions to overspray on the eyelid
Mystic Value Proposition For Caregivers and Institutions
Mystic drug delivery systems provide patients residing in healthcare, nursing homes and assisted-care living facilities with all the same benefit as consumers. Additionally, caregivers and institutional environments such as hospitals, nursing homes, assisted-care living environments will benefit in the following areas:
• Improved efficiency of caregiver staff in the time required to administer eye drops to
patients during rounds
• Reduction of potential liability as a result of accidental eye injuries incurred due to faulty
administration
• Reduction of waste and cost associated with inexact administration and spillage
• Enhanced capability to administer ophthalmic drugs to uncooperative elderly and
pediatric patients
• Reduced cross-contamination arising from use of large institutional eye drop bottles
• More efficient and accurate inventory management and billing record management
Mystic Value Proposition For Pharma/BioTech Manufacturers
Mystic's innovative drug delivery systems provide Pharma/BioTech Manufacturers with unique competitive advantages for the key stakeholders spanning the entire pharmaceutical value chain including the consumer, pharmacists, prescribing physician and manufacturer that will drive market share growth for targeted therapeutic drug or biologic products:
• Accelerated product adoption (and overall category growth) driven by
innovative drug delivery system that can enhance patient compliance, convenience
and ease of use
• Enhanced competitive positioning for new drugs introductions,
• Product life extension of proprietary drugs coming off patent.
• Competitive differentiation for generic or branded generic drugs using novel drug delivery
system
• Design for manufacturability” device and unit dose packaging can be cost effectively
produced at global scale volumes
• Integrated device security key prevents competitive encroachments in customer base within
targeted therapeutic categories.
The eye dropper has been the predominate delivery system for ophthalmic drugs for over a century. Ninety-five percent of all ophthalmic drugs are delivered by an eye drop bottle. While inexpensive to manufacture, the eye drop bottle creates a plethora of problems for people who use it. The root of these problems lies in several factors related to the physics of eye drop, fluid dynamics and gravity.
The eye drop bottle relies upon gravity to move the drop from the tip of the bottle to the eye. Generally an eye drop must reach a size of about 40 microliters before it will fall from the tip of the bottle. Unfortunately, the human eye can only hold a drop of 12 microliters before it will overflow. Hence, two-thirds of every drop is wasted. This drug overflow creates a cascade of higher order problems for people such as the inconvenience of the "wet face" syndrome, waste of expensive medications, allergic reactions on the eyelids and a variety of potential health risks associated with inaccurate dosing of a pharmaceutical drug.
Effective eye drop administration from a bottle is further complicated by the challenges of having to tip back the head, while positioning a very small bottle over the eye, while squeezing the bottle with the appropriate level of force (too little force and the drop will not form and drop, too much force and you feel like you've turned on the garden hose), while holding the bottle steady so as not to miss the eye. All this while attempting to not look at the bottle as you are dispensing the drug. Add the physical challenges often faced by the elderly, compounded by the need for multiple daily administration of ophthalmic drugs by chronic sufferers and you can begin to grasp the nature of the Eye Drop Bottle Dilemma.
Why no one has solved this problem in the past one hundred years with all the advancements in science and technology is an interesting mystery. Finally, Mystic Pharmaceuticals has the solution.
Mystic Value Proposition For Consumers
Mystic devices are designed to provide the consumer with an easy, convenient and safe way to self-administer ophthalmic drugs. Each device carries a multiple day supply of individual unit dose blisters. The device can administer drugs to the eye in a wide range of normal physical positions. The eyecup aids the user in exact positioning of the device and in holding the eyelid in the optimum position. The device operates with the push of a button and delivers a precise dose to a precise location in the eye safely, comfortably with minimum waste. Mystic drug delivery systems are designed to provide consumers with the following benefits.
• Precision dosing, precision drug delivery
• Reduced waste (and cost) arising from errors in drug administration
• Reduced health risks resulting from under/over drug administration
• Reduces flow of excess medication through nasolacrimal duct and resulting systemic uptake
• Elimination of the drug preservatives improving comfort and reducing the risk of eye irritation
• Reduction of waste arising from discards of partially used bottles
• Reduced risk of accidental "poke" or injury to the eye
• More flexible range of physical orientations during drug administration
• Enhanced compliance tracking to prescribed use
• Ease, speed and convenience of drug administration process
• Elimination of the "wet face" syndrome and allergic reactions to overspray on the eyelid
Mystic Value Proposition For Caregivers and Institutions
Mystic drug delivery systems provide patients residing in healthcare, nursing homes and assisted-care living facilities with all the same benefit as consumers. Additionally, caregivers and institutional environments such as hospitals, nursing homes, assisted-care living environments will benefit in the following areas:
• Improved efficiency of caregiver staff in the time required to administer eye drops to
patients during rounds
• Reduction of potential liability as a result of accidental eye injuries incurred due to faulty
administration
• Reduction of waste and cost associated with inexact administration and spillage
• Enhanced capability to administer ophthalmic drugs to uncooperative elderly and
pediatric patients
• Reduced cross-contamination arising from use of large institutional eye drop bottles
• More efficient and accurate inventory management and billing record management
Mystic Value Proposition For Pharma/BioTech Manufacturers
Mystic's innovative drug delivery systems provide Pharma/BioTech Manufacturers with unique competitive advantages for the key stakeholders spanning the entire pharmaceutical value chain including the consumer, pharmacists, prescribing physician and manufacturer that will drive market share growth for targeted therapeutic drug or biologic products:
• Accelerated product adoption (and overall category growth) driven by
innovative drug delivery system that can enhance patient compliance, convenience
and ease of use
• Enhanced competitive positioning for new drugs introductions,
• Product life extension of proprietary drugs coming off patent.
• Competitive differentiation for generic or branded generic drugs using novel drug delivery
system
• Design for manufacturability” device and unit dose packaging can be cost effectively
produced at global scale volumes
• Integrated device security key prevents competitive encroachments in customer base within
targeted therapeutic categories.